Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

The latest buyout Novo Nordisk is trying to pull off is putting it in a direct confrontation with another beaten-down ...

The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled Investigation ...

Pressured by its key shareholder, the Novo Nordisk Foundation, the company said its chairman, Helge Lund, will resign. In addition to Lunde, the company's vice chair, Henrik Poulsen, will step down, ...

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug. Omeros spent the first weeks of the year ...

Novo Nordisk said Thursday it was buying US biotech firm Akero Therapeutics, which is developing treatments for a number of metabolic diseases, for $4.7 billion. The Danish firm, the maker of ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...